# Cidara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cidara-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.cidara.com
- Total disclosed funding: $72M
- Latest round: Series B (Feb 13, 2015)
- Investors on record: 11

## About

Cidara Therapeutics, Inc. is a US-based biotechnology company focused on the development of targeted immunotherapies to improve treatment outcomes for serious diseases, utilizing innovative drug-Fc conjugate technology.Founded in 2013 and headquartered in San Diego, US, Cidara Therapeutics specializes in creating innovative therapies for diseases such as cancer and infections. The company has engaged in multiple funding rounds, with the most recent being a Private Placement/Follow on that raised USD 17.50 mn on March 2, 2023, contributing to a total amount raised of USD 240.00 mn.Cidara Therapeutics specializes in developing targeted immunotherapies aimed at enhancing patient outcomes in the treatment of serious diseases. The company’s primary innovation is its Cloudbreak platform, which creates drug-Fc conjugates (DFCs) that combine targeted small molecules and peptides with human antibody fragments. These DFCs are engineered to selectively inhibit specific disease targets while simultaneously activating the immune system, potentially transforming the standard of care for patients. The end users of these therapies include healthcare providers and patients suffering from conditions such as cancer and infectious diseases. Cidara's products are designed for deployment in major pharmaceutical markets, including North America and Europe, where there is significant demand for advanced therapeutic solutions.Cidara Therapeutics generated revenue of USD 63.91 mn in 2023. The company's EBITDA for the same year was USD -24.29 mn. Cidara primarily generates revenue through partnerships and collaborations within the biopharmaceutical sector, engaging in B2B transactions with healthcare institutions and pharmaceutical companies, providing innovative immunotherapies as part of strategic alliances.Cidara Therapeutics plans to utilize the funds raised in its March 2023 private placement to support the development of new therapies and expand its product offerings. The company aims to launch new products derived from its Cloudbreak platform, with specific timelines for their release to be announced. Additionally, Cidara is targeting expansion into new markets beyond North America and Europe, with plans for geographic growth that include Asia-Pacific regions by 2024.

## Funding rounds

- Series B, Feb 13, 2015, $42M — Frazier Healthcare Partners, InterWest Partners, Portola Ventures, 5AM Ventures, Aisling Capital, Fidelity Investments, VenBio, RA Capital Management, Rock Springs Capital, Sabby Capital, Perceptive Advisors
- Series A, Jun 30, 2014, $30M — Frazier Healthcare Partners, InterWest Partners, 5AM Ventures, Aisling Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A, Series B
- Portola Ventures (https://capitalatlas.ai/funds/portola-ventures) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B